Cisplatin + Gemcitabine + Nadroparin + Pemetrexed

This is a multi-drug chemotherapy regimen combining four distinct medications: 1. **Cisplatin**: A platinum-based chemotherapy drug that forms DNA adducts, leading to DNA damage and inhibition of DNA replication and transcription. 2. **Gemcitabine**: A nucleoside analog chemotherapy drug that incorporates into DNA, inhibiting DNA synthesis and repair. 3. **Nadroparin**: A low molecular weight heparin (LMWH) primarily acting as an anticoagulant by potentiating antithrombin III, leading to inactivation of Factor Xa. Its inclusion in a chemotherapy regimen is often for prophylaxis or treatment of thromboembolic events, which are a common complication in cancer patients. 4. **Pemetrexed**: An antifolate antineoplastic agent that inhibits several folate-dependent enzymes involved in pyrimidine and purine synthesis, including thymidylate synthase and dihydrofolate reductase. While the specific four-drug combination of cisplatin + gemcitabine + nadroparin + pemetrexed is not explicitly described as a standard regimen, the individual components and some two-drug combinations (e.g., cisplatin + gemcitabine, cisplatin + pemetrexed) are well-established in cancer treatment. The combination of cisplatin and gemcitabine (GC or GemCis) is widely used for various cancers, and pemetrexed is a key agent in non-small cell lung cancer and malignant pleural mesothelioma.